

# Pneumococcal infections in children with sickle cell disease before and after pneumococcal conjugate vaccines

Thomas V. Adamkiewicz,<sup>1,2</sup> Marianne E. M. Yee,<sup>2,3</sup> Stepy Thomas,<sup>4-6</sup> Amy Tunali,<sup>4,6</sup> Kristina W. Lai,<sup>3,7</sup> Folashade S. Omole,<sup>1</sup> Peter A. Lane,<sup>2,3</sup> and Inci Yildirim<sup>2,8-10</sup>

<sup>1</sup>Department of Family Medicine, Morehouse School of Medicine, Atlanta, GA; <sup>2</sup>Department of Pediatrics, Emory University School of Medicine, Atlanta, GA; <sup>3</sup>Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA; <sup>4</sup>Department of Medicine, Emory University School of Medicine, Atlanta, GA; <sup>5</sup>Georgia Emerging Infections Program, Atlanta, GA; <sup>6</sup>Atlanta Veterans Administration Health System, Decatur, GA; <sup>7</sup>University of California, Davis, CA; <sup>8</sup>Department of Pediatrics, Yale University School of Medicine, New Haven, CT; <sup>9</sup>Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT; and <sup>10</sup>Yale Center for Infection and Immunity, Yale Institute of Global Health, New Haven, CT

## Key Points

- Invasive pneumococcal infection in children with SCD has declined significantly with PCV7/PCV13 but remains a life-threatening risk.
- PPSV23 and new vaccines PCV15, PCV20, and PCV21 include 62%, 16%, 51%, and 92% of IPD serotypes not included in PCV13, respectively.

Children with sickle cell disease (SCD) are at increased risk of invasive pneumococcal disease (IPD). Over 25 years, the Georgia Emerging Infections Program/Centers for Disease Control and Prevention Active Bacterial Core Surveillance network identified 104 IPD episodes among 3707 children with hemoglobin SS (HbSS) or HbSC aged <10 years, representing 6% of IPD in Black or African American children residing in Metropolitan Atlanta (reference population). Children with IPD and HbSS/SC were older than those with IPD in the reference population ( $P < .001$ ). From 1994-1999 to 2010-2018, IPD declined by 87% in children with HbSS aged 0 to 4 years, and by 80% in those aged 5 to 9 years. However, IPD incidence rate ratios when comparing children with SCD with the reference population increased from 20.2 to 29.2 over these periods. Among children with HbSS and IPD, death declined from 14% to 3% after 2002, and meningitis declined from 16% to 8%. Penicillin resistance was more prevalent in children with SCD before 7-valent pneumococcal conjugate vaccine (PCV7) licensure. After 2010, all IPD serotypes were not included in the 13-valent PCV (PCV13). Within 3 years of vaccination, the effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) against non-PCV13 serotypes included in PPSV23 plus 15A/15C was 92% (95% confidence interval, 40.8- 99.0,  $P = .014$ ; indirect-cohort effect adjusted for age and hydroxyurea). PPSV23 would cover 62% of non-PCV13 serotype IPD in children with SCD, whereas PCV15, PCV20, and PCV21/V116 (in development) could cover 16%, 51%, and 92%, respectively. Although less frequent, IPD remains a life-threatening risk in children with SCD. Effective vaccines with broader coverage could benefit these children.

## Introduction

Sickle cell disease (SCD) is an inherited  $\beta$ -hemoglobinopathy that causes hemoglobin to polymerize and form rigid red blood cells and occlude the microvasculature.<sup>1</sup> Children with SCD develop splenic dysfunction in infancy<sup>2,3</sup> and, thus, are at risk of invasive bacterial infections including *Streptococcus*

Submitted 28 December 2022; accepted 13 July 2023; prepublished online on *Blood Advances* First Edition 12 September 2023; final version published online 3 November 2023. <https://doi.org/10.1182/bloodadvances.2022009643>.

Data that support the findings of this study are available upon reasonable request from the corresponding author, Thomas V. Adamkiewicz, ([tadamkiewicz@msm.edu](mailto:tadamkiewicz@msm.edu)).

The full-text version of this article contains a data supplement.

© 2023 by The American Society of Hematology. Licensed under [Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International \(CC BY-NC-ND 4.0\)](https://creativecommons.org/licenses/by-nc-nd/4.0/), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

*pneumoniae*. Before the general adoption of empiric antibiotics for fever<sup>4</sup> and penicillin prophylaxis,<sup>5</sup> ~1 in 10 children per year aged <5 years with hemoglobin SS (HbSS) developed invasive pneumococcal disease (IPD).<sup>4</sup> IPD case fatality ranged from 12.5%<sup>6</sup> to 25%<sup>7</sup> or 27%,<sup>4</sup> and in the Cooperative Study of Sickle Cell Disease, IPD accounted for 32% of all causes of death in individuals with SCD aged <20 years.<sup>8</sup> Powars et al demonstrated that IPD-related deaths and meningitis were preventable by the rapid institution of parenteral antibiotic therapy in children with HbSS and fever.<sup>4</sup> Systematic collection of blood cultures before the administration of antibiotics also increased the detection of bacteremia.<sup>4</sup> The Prophylactic Penicillin Study (PROPS) in children with HbSS<sup>5</sup> showed 85% reduction in IPD with penicillin prophylaxis compared with placebo,<sup>5</sup> leading to the 1987 National Institutes of Health Consensus Conference statement recommending universal newborn screening for SCD and routine oral penicillin prophylaxis.<sup>9</sup> In a subsequent trial (PROPS II), a 50% reduction in IPD incidence rate was noted in children with HbSS aged ≥5 years on penicillin prophylaxis. However, because the study was underpowered and did not reach statistical significance,<sup>10</sup> routine use of penicillin prophylaxis in those aged ≥5 years was not recommended.<sup>11</sup> After institution of penicillin prophylaxis, both adherence<sup>12</sup> and the emergence of antibiotic resistance<sup>13</sup> presented challenges to this IPD preventive strategy.

Children with SCD reportedly mount an adequate functional immune response after pneumococcal conjugated vaccination, as measured by opsonophagocytic assay.<sup>14-16</sup> Within a single center, 3 years after the general licensure of the 7-valent pneumococcal conjugate vaccine (PCV7) in 2000, IPD rates decreased by 77% in children with SCD aged 0 to 10 years.<sup>17</sup> However, by 2009, using US national surveillance data, IPD reduction in children with SCD aged <18 years was estimated at only 53%, compared with 74% in the general population.<sup>18</sup> After PCV13 licensure in 2010, IPD incidence rates decreased further in the general population.<sup>19,20</sup> Two additional PCVs were approved in 2021, PCV15<sup>21</sup> and PCV20.<sup>22</sup>

To better understand IPD incidence and serotype trends in children with SCD, this study extends previously published IPD surveillance data<sup>13,17</sup> to include cases of IPD in relation to PCV7 and PCV13 licensure in children with SCD and a reference population over a 25-year period.

## Methods

### Study population

The Georgia Emerging Infections Program<sup>23</sup> identifies all IPD occurring in Metropolitan Atlanta since 1994 as part of a nationwide Centers for Disease Control and Prevention (CDC)-funded Active Bacterial Core Surveillance network. Initially the catchment area included 8 mostly urban counties (population of 3.1 million, with 34.5% Black or African American residents, per the 2000 census; thereafter a population of 4.2 million, with 42.7% Black or African American residents, per the 2020 census). Twelve additional counties were added after 1996 (population of 1 and then 1.7 million, with 10.9% and 19.4% Black or African American residents, per the 2000 and 2020 censuses, respectively).<sup>24</sup> The reference population was defined as the total number of Black or African American children residing in counties included in the study by year and age, as provided by the Georgia Department of Public Health Online Analytical Statistical Information System.<sup>25</sup>

### Population of children with SCD

Targeted newborn screening for hemoglobinopathies was mandated in Georgia in 1978<sup>26,27</sup> and had expanded to universal screening in 1998.<sup>26</sup> This study used 2 databases of children with SCD aged 0 to 9 years seen once or more at any of the only 3 pediatric hospitals providing specialized care for children with hemoglobinopathies serving the region examined (Egleston, Scottish Rite, and Grady/Hughes Spalding Hospitals, merged since 1998 under Children's Healthcare of Atlanta [CHOA]). The first database was used to support IPD surveillance from 1994 to 2002 and included clinical information starting in 1984, as previously described.<sup>13,17</sup> The second data set (2002-2018) was derived from the SCD Clinical Database at CHOA, which, since 2004, has contributed data to statewide CDC-sponsored surveillance programs.<sup>28</sup> Both data sets were merged with the Georgia Emerging Infections Program IPD surveillance database at the Atlanta Veteran Administration Medical Center.<sup>23</sup> To assess whether the study cohort was representative of children with SCD in the region, data were compared to a cohort of newborn infants screened for SCD.<sup>28</sup> Standard of care included penicillin prophylaxis<sup>29</sup> and 23-valent pneumococcal polysaccharide vaccine (PPSV23) vaccination<sup>29</sup> for the entire period, with the addition of PCV7<sup>17,30</sup> and PCV13<sup>31</sup> after respective licensures (2000 and 2010, respectively), and hydroxyurea use.<sup>32,33</sup>

### Vaccination data

The vaccination status of children with SCD and IPD was obtained from the state mandatory vaccination registry (Georgia Registry of Immunization Transactions and Services) and chart review.<sup>17,34</sup> All serotypes not included in PCV13 were defined as non-PCV13 serotypes. Serotype 15BC indicates typing that could be either 15B or 15C. Vaccine-related serotype 6C was considered covered in PCV21/V1163<sup>35</sup>; 15A covered in PPSV23<sup>35</sup>; and 15C covered in PPSV23,<sup>35,36</sup> PCV20,<sup>37</sup> and PCV21/V116.<sup>35</sup>

### Laboratory data

Hemoglobinopathy diagnosis was previously determined by complete blood count, electrophoresis, or high-performance liquid chromatography separation as part of the databases of children with SCD,<sup>28</sup> or established from laboratory records and chart review, as previously described.<sup>13,17</sup> Children with HbSS and Sp<sup>0</sup> thalassemia were included in a single HbSS group and differentiated from children with HbSC. Consistent with previous publications,<sup>13,17</sup> children with HbSβ<sup>+</sup> thalassemia and those with rare SCD genotypes (eg, HbSD and Hb SO-Arab) were excluded. Invasive pneumococcal disease (IPD) is defined as *S pneumoniae* identified from a sterile, invasive body site. Antibiotic susceptibility and serotype testing were performed at the CDC.<sup>38</sup> Oral penicillin minimal inhibitory concentration breakpoints were defined as follows: susceptible, ≤0.06 μg/mL; intermediate, 0.12 to 1 μg/mL; and resistant, ≥2 μg/mL.<sup>39</sup> Serotype was ascertained by latex agglutination, Quellung reaction, polymerase chain reaction, or whole-genome sequencing.<sup>38</sup>

### Pooled data

To compare serotype distribution and vaccination coverage of PPSV23, PCV15, PCV20, and PCV21 to other data sources, reports of IPD in children with SCD outside of Georgia were

identified by PubMed, Google Scholar (terms sickle cell and pneumococcal and/or bacterial and/or infectious), crossreferences, or prior surveillance data.<sup>13,40</sup> IPD with an unknown or indeterminate number of patients or serotypes were excluded. A study of nasopharyngeal carriage was examined separately.<sup>41</sup>

## Statistical analysis

**Aims.** The principal aim of the study was to assess IPD incidence rate changes before and after the introduction of PCVs, by age group in children with HbSS or HbSC, and the reference population. Secondary aims included assessing changes in IPD penicillin susceptibility and serotype distribution before and after PCV licensure. The effectiveness of PPSV23 on non-PCV13 serotypes and the potential coverage by PPSV23, PCV15, PCV20, and PCV21 were evaluated.

**Incidence rate, incidence rate ratios, and relative risk.** The first and last dates of service were identified for each patient. Person-time for each patient was defined as the beginning of the study period or the date of the first health care visit. The last observation date was the last recorded visit date, or the end of the study period, whichever came first.<sup>17</sup> If a patient moved or died, the last recorded visits counted as the date of censor. For the reference population, IPD incidence rates in Black or African American children were calculated by dividing the total number of IPD by the total number of children estimated living in the region examined for the same year, group of counties, and age. Data were grouped into 3 study periods: 1994-1999 (pre-PCV7 era), 2000-2009 (PCV7 era), and 2010-2018 (PCV13 era).

Age distribution differences were estimated by Wilcoxon signed-rank test; incidence rate and incidence rate ratios confidence intervals (CIs) were estimated by Poisson regression.<sup>42</sup> Frequency distribution differences were estimated by relative risk, and the strength of association by Fisher exact test.

**Indirect-cohort PPSV23 vaccine effect.** PPSV23 vaccine effect for non-PCV13 serotypes was assessed by the indirect-cohort method.<sup>13,43</sup> The indirect-cohort effect assumes that among individuals vaccinated with PPSV23, “a” is the number of IPD with serotypes included in PPSV23, and “b” is the number of IPD with serotypes not included in the vaccine. Among unvaccinated individuals, “c” is the number of IPD with serotypes included in PPSV23, and “d” is the number of IPD with serotypes not included in the vaccine. The effect is calculated as  $\hat{E} = 1 - (ad/bc)$ .<sup>43</sup> This method allows estimation of PPSV23 effectiveness with data limited to individuals with IPD, without needing vaccination data from control individuals without infection.<sup>13,43,44</sup> PPSV23 vaccine effect was assumed limited to 3 years after vaccination<sup>13,45</sup> and estimated by logistic regression<sup>13</sup> controlling for age and hydroxyurea use.

Strength of association was defined as significant at an  $\alpha$  level  $<.001$  and approaching significance at an  $\alpha$  level  $<.050$  to  $.001$  (statistical package, SAS 9.4, Cary, NC). The Emory institutional review board reviewed and approved the study under data use agreements in place between Morehouse School of Medicine, the Atlanta Veteran Administration Medical Center, and CHOA.

## Results

### Population description

Between 1994 and 2018, 3707 children aged  $<10$  years, 2628 with HbSS (71%) and 1079 with HbSC (29%), were seen at least once in  $\geq 1$  of the 3 pediatric hospitals serving the region examined, for a total of 16 144 person-years of observation, whereas the reference population represented 5 923 730 person-years of observation. Children with SCD in this study corresponded to 2.7 per 1000 person-years of observation among Black or African American children in the region during the period examined.

Approximately 2.9 of 1000 Black or African American infants born in the study region were diagnosed with HbSS/SC (2009-2019: 948 children born with HbSS 485 with HbSC, per the Georgia Sickle Cell Data Collection program of the CDC,<sup>28</sup> unpublished, of 499 137 Black or African American newborn infants born in the region<sup>25</sup>). The calculated observation time represents 94.9% of the expected time for the entire birth cohort of children with HbSS/SC in the region. Among infants with SCD in GA, 97% were identified as African American or Black,<sup>46</sup> and 89% in the 20 surveillance counties (2009-2019, the Georgia Sickle Cell Data Collection program,<sup>28</sup> unpublished).

There were 104 cases of IPD in SCD (84% HbSS, 16% HbSC), representing 6% of the 1858 IPD cases in the reference population. Case distribution over time was 67 (64%) in the pre-PCV period (1994-1999), 20 (19%) in PCV7 period (2000-2009), and 17 (16%) in PCV13 period (2010-2018). Infections occurred in boys in 51%, 53%, and 56% of IPD in children with HbSS, HbSC, or the reference population, respectively. Overall children with SCD and IPD were older compared with the reference population (aged 5-9 years vs aged 0-4 years; relative risk, 2.9; 95% CI, 2.0-4.1;  $P < .001$ ). Median patient age at IPD onset was as follows: HbSS, 3 years (interquartile range [IQR], 1-5), HbSC, 2 years (IQR, 1-4), and reference population, 1 year (IQR, 0-2; reference population vs HbSS,  $P < .0001$ ; vs HbSC,  $P = .0249$ ). In the reference population, the number of children aged 5 to 9 years with IPD increased from 6% (66/1030) in the period 1994-1999 to 12% (101/828,  $P < .0001$ ) in the period 2000-2018; in SCD, older age at IPD onset was 20% (10/50) between 1994 and 1999 and 31% (17/54,  $P = .2630$ ) between 2000 and 2018.

### Incidence rate and incidence rate ratios

Table 1 shows IPD incidence rates for each era for children with HbSS or HbSC, and the reference population. Overall IPD incidence rates, meningitis, and death declined significantly in both age groups (aged 0-4 years and 5-9 years) of the SCD and reference populations after PCV7 (2000-2009) and PCV13 (2010-2018) licensure (Figure 1). Table 2 shows IPD incidence rate ratios for the PCV7 and the PCV13 eras, as compared with the pre-PCV era, for those with HbSS or HbSS/SC, and for reference populations, demonstrating substantial risk reductions overall for each complication (meningitis and death) in all populations, over time. However, when IPD incidence rates in children with SCD were compared with those in the reference population, IPD incidence rate ratios increased over time (Table 3).

**Table 1. IPD incidence rates in children with HbSS or SCD (HbSS/SC), or a reference population from Metropolitan Atlanta, GA**

Outcome/serotypes	Population	Age, y	IPD/person-years			IPD incidence rates (/1000 person-years) (95% CI)		
			Pre-PCV period, 1994-1999	PCV7 period, 2000-2009	PCV13 period, 2010-2018	Pre-PCV period, 1994-1999	PCV7 period, 2000-2009	PCV13 period, 2010-2018
All IPD	HbSS	0-4	30/952	23/1 994	9/2 297	31.5 (22.0-45.1)	11.5 (7.7-17.4)	3.9 (2.0-7.5)
		5-9	10/949	9/2 312	6/2 867	10.5 (5.7-19.6)	3.9 (2.0-7.5)	2.1 (0.9-4.7)
		0-9	40/1 901	32/4 306	15/5 164	21.0 (15.4-28.7)	7.4 (5.3-10.5)	2.9 (1.8-4.8)
	HbSC	0-4	10/390	1/841	4/1 041	25.6 (13.8-47.7)	1.2 (0.2-8.4)	3.8 (1.4-10.2)
		5-9	0/372	2/973	0/1 158	-	2.1 (0.5-8.2)	-
		0-9	10/761	3/1 814	4/2 198	13.1 (7.1-24.4)	1.7 (0.5-5.1)	1.8 (0.7-4.8)
	HbSS/SC	0-4	40/1 342	24/2 835	13/3 338	29.8 (21.9-40.6)	8.5 (5.7-12.6)	3.9 (2.3-6.7)
		5-9	10/1 320	11/3 286	6/4 024	7.6 (4.1-14.1)	3.3 (1.9-6.0)	1.5 (0.7-3.3)
		0-9	50/2 662	35/6 120	19/7 362	18.8 (14.2-24.8)	5.7 (4.1-8.0)	2.6 (1.6-4.0)
Reference	0-4	964/550 030	545/1 138 977	182/1 183 798	1.8 (1.6-1.9)	0.5 (0.4-0.5)	0.2 (0.1-0.2)	
	5-9	66/559 250	66/1 220 492	35/1 271 183	0.1 (0.1-0.2)	0.1 (<1-0.1)	<1 (<1 to <1)	
	0-9	1030/1 109 280	611/2 359 469	217/2 454 981	0.9 (0.9-1.0)	0.3 (0.2-0.3)	0.1 (0.1-0.1)	
Meningitis	HbSS	0-9	5/1 901	6/4 306	1/5 164	2.6 (1.1-6.3)	1.4 (0.6-3.1)	0.2 (<1-1.4)
	Reference	0-9	32/1 109 280	34/2 359 469	17/2 454 981	<1 (<1 to <1)	<1 (<1 to <1)	<1 (<1 to <1)
Death	HbSS	0-9	6/1 901	1/4 306	1/5 164	3.2 (1.4-7.0)	0.2 (<1-1.6)	0.2 (<1-1.4)
	Reference	0-9	14/1 109 280	11/2 359 469	5/2 454 981	<1 (<1 to <1)	<1 (<1 to <1)	<1 (<1 to <1)
PCV13*	HbSS/SC	0-9	11/1 901	8/6 120	0/7 362	1.5 (0.7-2.7)	1.1 (0.5-2.1)	-
	Reference	0-9	112/1 109 280	194/2 359 469	53/2 454 981	<1 (<1-0.1)	0.1 (0.1-0.1)	<1 (<1 to <1)
6A	HbSS/SC	0-9	11/1 901	1/6 120	0/7 362	1.5 (0.7-2.7)	0.1 (<1-0.8)	-
	Reference	0-9	71/1 109 280	36/2 359 469	9/2 454 981	<1 (<1 to <1)	<1 (<1 to <1)	<1 (<1 to <1)
19A	HbSS/SC	0-9	0/1 901	7/6 120	0/7 362	-	1.0 (0.4-2.0)	-
	Reference	0-9	29/1 109 280	141/2 359 469	34/2 454 981	<1 (<1-0.1)	0.1 (0.0-0.1)	<1 (<1 to <1)
Non-PCV13	HbSS/SC	0-9	3/1 901	17/6 120	17/7 362	0.4 (0.1-1.2)	2.3 (1.3-3.7)	2.3 (1.3-3.7)
	Reference	0-9	39/1 109 280	136/2 359 469	121/2 454 981	<1 (<1 to <1)	0.1 (<1-0.1)	<1 (<1-0.1)
15B/15C	HbSS/SC	0-9	2/1 901	3/6 120	4/7 362	0.3 (0.0-1.0)	0.4 (0.1-1.2)	0.5 (0.1-1.4)
	Reference	0-9	4/1 109 280	23/2 359 469	19/2 454 981	<1 (<1 to <1)	<1 (<1 to <1)	<1 (<1 to <1)

\*Non-PCV7 serotypes; data sources: Children's Healthcare of Atlanta; Georgia Department of Public Health Online Analytical Statistical Information System<sup>25</sup>; and the Georgia Emerging Infections Program, CDC Active Bacterial Core Surveillance network.<sup>23</sup>

## Clinical findings

Among 8 deaths attributed to IPD in children with SCD, all occurred in children with HbSS. Mortality of IPD in HbSS was 9% (8/87): 8% (5/62) of children aged 0 to 4 years and 12% (3/25) of those aged 5 to 9 years. Case fatality before 2002 was 14% (7/50), and 3% (1/37) thereafter ( $P = .1306$ ). Among children with HbSS and IPD, meningitis occurred in 12 (14%) overall, 15% (9/62) in those aged 0 to 4 years and 12% (3/25) in those aged 5 to 9 years, with 9 cases (18%) and 4 (11%) before and after 2002, respectively ( $P = .5446$ ). One child aged 0 to 4 years with HbSC developed meningitis. In the reference population case fatality before and after 2002 was 1.4% and 2.0% ( $P = .3312$ ), respectively, and morbidity from meningitis increased (3.6% vs 6.4%,  $P = .0078$ , refer to supplemental Data).

After 2002, when PCV7 was generally introduced, clinical information was available in 93% (39/42) of IPD episodes. Antibiotic prophylaxis was prescribed in 77% (20/26) of children aged 0 to 4 years, and in 38% (5/13) aged 5 to 9 years. Hydroxyurea administration was recorded in 6 (23%) children aged 0 to 4 years and in 5 (38%) aged 5 to 9 years. Four (10%) children had a history of


surgical splenectomy before IPD, and 2 (5%) had received bone marrow transplantation.

## Penicillin susceptibility

Reference laboratory penicillin susceptibility measures were available in 94 (90%) IPDs from children with SCD, and from 1530 (83%) IPD in the reference population. Before PCV7 licensure, IPD in patients with SCD were less likely to be penicillin susceptible compared with the reference population. However, after PCV7 licensure there was no significant difference (supplemental Table 5). In the PCV13 era, no isolate from children with HbSS was resistant to penicillin at a minimal inhibitory concentration of  $\geq 2 \mu\text{g/mL}$ .

## IPD serotypes

Serotype data were available in 94% IPD in children with SCD, and in 84% IPD in the reference population. Compared with the reference population, children with HbSS were less likely to be infected with serotype 9V (0% vs 5%,  $P = .0299$ ) and serotype 14 (8% vs 24%;  $P = .001$ ); and more likely to be infected with serotype 23F (16% vs 7%;  $P = .008$ ) or serotype 15BC (8% vs 3%;



**Figure 1.** IPD trends (A-D). IPD in children with SCD Hb type and reference population, by age group. Red dashed line: IPD incidence rate level in children aged  $\geq 5$  years with HbSS before PCV licensure, an age group that was not recommended to take penicillin prophylaxis.<sup>9,10</sup>

$P = .011$ ). After PCV13 licensure, no IPD with any PCV13 serotype occurred in children with SCD.

Among non-PCV13 IPD serotypes in children with SCD, 15BC was the most frequently identified in 9 cases (24%), followed by 15A, 22F, or 23B, in 4 (11%) cases each (Table 4). IPDs with non-PCV13 serotypes were less frequent in children with SCD aged 0 to 4 years compared with those aged 5 to 9 years (17% vs 42%,  $P = .011$ ), similar to the reference population (18% vs 36%,  $P < .001$ ). IPD incidence rate ratio for non-PCV13 IPD increased after PCV7 licensure in the reference population (1.5, 95% CI, 1.1-2.1;  $P = .015$ ). A parallel trend was noted in children with SCD (2.2, 95% CI, 0.7-7.3;  $P = .181$ ; Tables 1 and 2).

Between 1994 and 2002, IPD serotypes associated with death included 19F in 3; 6A, 18C, and 23F (all covered in PCV7); and 15C (non-PCV7/PCV13). Meningitis was associated with serotypes 23F in 2 (17%), 6A, 14, 18C, and 19F (all covered in PCV7). Between 2002 and 2018 meningitis was associated with serotypes 6A, 12F, 15A, and 15B, and death with serotype 12F (4/5 non-PCV13 serotypes).

### HbSS vs HbSC

Overall, IPD was less frequent in children with HbSC compared with children with HbSS (1994-2018, incidence rate ratio HbSC

vs HbSS: 0.5; 95% CI, 0.3-0.8;  $P = .004$ ); this difference between HbSS and HbSC was most pronounced during the period 2000-2009 (incidence rate ratio, 0.2; 95% CI, 0.1-0.7;  $P = .013$ ; Table 2). Although there were no significant differences in serotype distribution between children with HbSS vs HbSC ( $P = .2207$ ), no children with HbSC were infected with serotypes 19A or 19F, whereas 7 children with HbSS developed IPD with serotype 19A (all during the PCV7 era) and 7 with serotype 19F. The frequency of IPD occurring at an older age (5-9 years) was 25 (29%) in HbSS and 2 (12%) in HbSC ( $P = .2265$ ).

### Pneumococcal vaccinations

Pneumococcal vaccination data were available in 93 (89%) IPD episodes in SCD. Before 2002, for children aged  $\geq 2$  years, at least 1 dose of PPSV23 had been received in 53% (16/30). After 2002, at least 1 dose of PPSV23 had been received in 67% (18 of 27), and 84% (31/37) had been received at least 1 dose of either PCV7 or PCV13 before infection. Within 3 years of vaccination, indirect-cohort effect estimates of PPSV23 vaccination on non-PCV13 serotypes included in PPSV23, plus vaccine-related serotypes 15A/15C<sup>35</sup> were 85.3% (95% CI, 30.0-96.9),  $P = .025$ , and 92.4% (95% CI, 40.8-99.0),  $P = .014$ , when adjusted for age and hydroxyurea use (refer to supplemental Table 6 for sensitivity analysis).

**Table 2. IPD incidence rates ratio as % change in children with HbSS, SCD (HbSS/SC), or reference population, comparing periods**

Outcome/serotypes	Population	Age, y	IPD incidence rate ratio as % change* (95% CI), P value		
			PCV7 vs pre-PCV period	PCV13 vs PCV7 period	PCV13 vs pre-PCV period
			2000-2009 vs 1994-1999	2010-2018 vs 2000-2009	2010-2018 vs 1994-1999
All IPD	HbSS	0-4	63.4 (37.0-78.7), <.001	66.0 (26.6-84.3), .006	87.6 (73.8-94.1), <.001
		5-9	63.1 (9.1-85.0), .030	46.2 (-33.8 to 80.9), .239	80.1 (45.4-92.8), .002
		0-9	64.7 (43.8-77.8), <.001	60.9 (27.8-78.8), .003	86.2 (75.0-92.4), <.001
	HbSC	0-4	95.4 (63.8-99.4), .003	-69.1 (-96.5 to 63.9), .294	85.0 (52.2-95.3), .001
		0-9	87.4 (54.3-96.5), .002	-9.1 (-79.7 to 75.4), .900	86.2 (55.8-95.7), <.001
	HbSS/SC	0-4	71.6 (52.9-82.9), <.001	54.0 (9.7-76.6), .024	86.9 (75.6-93.0), <.001
		5-9	55.8 (-3.9 to 81.2), .062	55.5 (-17.0 to 83.5), .111	80.3 (45.8-92.8), .002
		0-9	69.6 (53.1-80.2), <.001	54.9 (21.1-74.2), .005	86.3 (76.7-91.9), <.001
	Reference	0-4	72.7 (69.7-75.4), <.001	67.9 (62.0-72.8), <.001	91.2 (89.7-92.5), <.001
5-9		54.2 (35.5-67.4), <.001	49.1 (23.3-66.2), .001	76.7 (64.9-84.5), <.001	
0-9		72.1 (69.2-74.8), <.001	65.9 (60.1-70.8), <.001	90.5 (89.0-91.8), <.001	
Meningitis	HbSS	0-9	47.0 (-42.4 to 83.8), .294	86.1 (-13.4 to 98.3), .068	92.6 (37.0-99.1), .017
	Reference	0-9	50.0 (19.1-69.2), .005	51.9 (14.0-73.2), .014	76.0 (56.8-86.7), <.001
Death	HbSS	0-9	92.6 (38.9-99.1), .016	16.6 (-92.5 to 94.8), .898	93.9 (49.0-99.3), .010
	Reference	0-9	63.1 (18.6-83.2), .013	56.3 (-20.5 to 84.8), .125	83.9 (55.2-94.2), <.001
PCV13*	HbSS/SC	0-9	68.4 (21.4-87.3), .013	100.0 (62.2 to 100.0), **0.004	100.0 (91.9 to 100.0), **<.001
	Reference	0-9	18.6 (-2.7 to 35.5), .084	73.7 (64.4-80.6), <.001	78.6 (70.4-84.6), <.001
Non-PCV13	HbSS/SC	0-9	-59.4 (-88.1 to 27.8), .150	16.9 (-38.6 to 57.6), .590	-51.2 (-85.7 to 40.0), .252
	Reference	0-9	-39.0 (-57.3 to 12.9), .006	14.5 (-8.5 to 33.1), .210	-28.7 (-50.3 to 2.3), .067
15B/15C	HbSS/SC	0-9	34.8 (-74.4 to 89.1), .640	-9.8 (-79.8 to 75.2), .893	27.7 (-74.7 to 86.8), .708
	Reference	0-9	-63.0 (-87.2 to 6.5), .066	20.6 (-31.4 to 56.8), .457	-53.4 (-84.1 to 27.0), .165

For incidence rate ratio (IRR) of <1: % change = (1 - IRR) × 100; for IRR of ≥1: % change = (1 - 1/IRR) × 100.

\*Non-PCV7 serotypes.

\*\*Conditional maximum likelihood estimate of Rate Ratio; <https://www.openepi.com>

### PPSV23, PCV15, PCV20, and PCV21 coverage

Potential coverage of non-PCV13 isolates by PPSV23, PCV15, PCV20, and PCV21 vaccines for this study and pooled data, are presented in Table 4 and supplemental Table 8.

### Discussion

The present study assessed the IPD incidence rate over a quarter century in children with HbSS or HbSC aged <10 years, who were followed-up at the only pediatric hospital-based health care system providing specialized care for SCD, a cohort that accounted to ~95% of the expected person-time of observation estimated from

newborn screening results from the region examined. Compared with the period before the introduction of PCV7 in 2000, the overall IPD incidence rate in children aged 0 to 9 years with HbSS or HbSC during the PCV13 era decreased by 86%, pneumococcal meningitis by 91%, and death by 94%, in parallel to the general population. Nevertheless, after 2009, children with HbSS were 33 times more likely to develop IPD, 28 times more likely to have meningitis, and 95 times more likely to die from IPD compared with the reference population of Black or African American children. Indeed, overall incidence rates in children with HbSS/SC aged 0 to 9 years from 2010 to 2018 were ~2.7 times higher than that of the general population before PCV7 licensure (Figure 1). Children with

**Table 3. IPD incidence rates ratio in children aged 0 to 9 years with HbSS or HbSC compared with the reference population**

Outcome	Population	IPD incidence rate ratio, SCD vs reference population, (95% CI), P value			
		Pre-PCV period, 1994-1999	PCV7 period, 2000-2009	PCV13 period, 2010-2018	Overall period, 1994-2018
All IPD	HbSS	22.7 (16.3-30.8), <.001	28.7 (19.8-40.4), <.001	32.9 (18.8-54.1), <.001	24.4 (19.6-30.1), <.001
	HbSC	14.2 (7.6-26.4), <.001	6.4 (2.1-19.9), .001	20.6 (7.7-55.4), <.001	11.4 (7.0-18.3), <.001
	HbSS/SC	20.2 (15.1-26.6), <.001	22.1 (15.5-30.7), <.001	29.2 (17.8-45.7), <.001	20.5 (16.9-25.0), <.001
Meningitis	HbSS	73.0 (22.0-191.0), <.001	96.7 (36.9-219.6), <.001	28.0 (1.3-154.1), .038	69.0 (35.1-125.6), <.001
Death	HbSS	250.1 (88.4-639.4), <.001	49.8 (2.3-291.8), .022	95.1 (4.0-686.7), .013	138.9 (59.7-294.2), <.001

**Table 4. Non-PCV13 IPD in children with SCD and IPD, serotype coverage by PPSV23, PCV15, PCV20, and PCV21/V116**

Data	IPD	PPSV23 serotype		PPSV23* serotype		PCV15 serotype		PCV20 serotype		PCV21 serotype		Total non-PCV13 serotypes	
		n	%	n	%	n	%	n	%	n	%	n	%
Present†	All	11	30	23	62	6	16	19	51	34	92	37	100
	Meningitis	2	50	4	100	0	0	3	75	4	100	4	100
	Death	1	50	2	100	0	0	2	100	2	100	2	100
	Meningitis/death	3	50	6	100	0	0	5	83	6	100	6	100
Pooled‡	All	7	14	23	50	2	4	18	39	37	80	46	100
	Meningitis	0	0	1	50	0	0	1	50	1	50	2	100
	Death	0	0	4	67	0	0	3	50	5	83	6	100
	Meningitis/death	0	0	5	71	0	0	4	57	6	86	7	100
Present†† pooled‡	All	18	22	46	55	8	10	37	45	71	86	83	100
	Meningitis	2	33	5	83	0	0	4	67	5	83	6	100
	Death	1	13	6	75	0	0	5	63	7	88	8	100
	Meningitis/death	3	23	11	85	0	0	9	69	12	92	13	100

Serotype 15C assumed covered in PCV20<sup>37</sup>; and serotype 6C and 15C covered in PCV21.<sup>35</sup>

Each column is a different subgroup of the total. All non-PCV13 IPD, irrespective of period when these occurred.

\*Vaccine-related serotype 15A<sup>35</sup> and 15C<sup>35,36</sup> assumed to be covered in PPSV23.

†15BC in 9 cases (24%); 15A, 22F, or 23B in 4 (11%) cases each; 06C or 12F in 3 (8%) each; 33F or 35B in 2 (5%) each; 7C, 10A, 16F, 23A, or 38 in 1 (3%) case each.

‡IPD serotype data in children with SCD, from previously published data.<sup>13,40,49,50,71,72,73,74,75,76,77,78</sup>

SCD and IPD were significantly older than those in the reference population, suggesting that risk does not diminish after the fifth birthday as significantly in children with SCD as it does in the general population.

The incidence rate ratios of IPD increased in children with HbSS over time, as previously observed.<sup>18</sup> A possible explanation includes the continuing practice of obtaining blood cultures in all febrile children with SCD<sup>33,47</sup> whereas blood culture use decreased in children in the general population after PCV licensure.<sup>48</sup> Inadequate use of antibiotic prophylaxis<sup>12</sup> may also explain increased incidence rate ratios over time. Before PCV7,<sup>13</sup> children with SCD whose guardians reported taking penicillin prophylaxis before IPD were significantly more likely to be infected with penicillin-nonsusceptible isolates,<sup>13</sup> and in general, IPD resistance to penicillin was significantly higher in patients with SCD compared with in the general population.<sup>13</sup> In this study, after PCV7 introduction, no significant differences were noted in penicillin susceptibility. Another possible explanation may be differences in the relative invasive potential of non-PCV13 serotypes in children with SCD compared with in the reference population. Serotypes 15B and 15C were responsible for IPD in children who were older and were more frequent in children with HbSS after PCV7 licensure compared with in the reference population.

Among children with HbSS, IPD case fatality decreased from 14% before 2002 to 3% after 2002, when pneumococcal conjugate vaccines became widely available; the frequency of meningitis decreased from 16% to 8%. Notably, after 2002, 1 death and 2 of 3 cases of meningitis were due to non-PCV13 serotypes. Cases that occurred in children after bone marrow transplantation suggest the need for ongoing vigilance, even after curative therapy. In addition to prompt antibiotic administration, improved IPD case fatality and morbidity can be attributed to targeted vaccination after PCV7 licensure<sup>17</sup>; the disappearance of serotypes previously

associated with lethal IPD in children with HbSS, in particular 19F; and ascertainment of additional cases of meningitis and death before 2002.<sup>13,17</sup> Case fatality and morbidity from meningitis in the reference population did not follow these trends.

IPD frequency was lower in children with HbSC compared with those with HbSS,<sup>17,49</sup> consistent with the delayed development of functional asplenia in children with HbSC.<sup>2,3</sup>

Previous PPSV23 effectiveness estimation in children with SCD ranged from 63%<sup>44</sup> to 80%.<sup>13</sup> The latter estimation was based on the assumption that the vaccine protective effect was limited to the first 3 years after vaccination, because the immune response 3 to 7 years after vaccination is poor.<sup>45</sup> Within the same assumption, PPSV23 appeared effective against non-PCV13 serotypes included in PPSV23, plus vaccine-related serotypes 15A<sup>35</sup> and 15C.<sup>35,36</sup> Yet, approximately a third of children aged  $\geq 2$  years with IPD had not received a first dose of PPSV23, and over 80% of children aged  $>5$  years had not received a second dose, representing an opportunity to improve coverage.

In children with SCD from the same region, an analysis of IPD that occurred during targeted vaccination, within the first 3 years after PCV7 licensure,<sup>17</sup> showed that children with SCD were, overall, more likely to be vaccinated than children in the general population.<sup>17</sup> Sixty-two percent of children with SCD in the first decade of life received  $\geq 1$  doses of PCV7, with a direct protective effect estimated between 81% and 84.5% in adjusted models.<sup>17</sup> Two years after licensure, when herd immunity was not widespread, the crude direct protective effect was 88.5%.<sup>17</sup> In this analysis, IPD rates in children with SCD aged  $\geq 5$  years were higher than those reported in PROPS II,<sup>10</sup> and decreased significantly after PCV7 licensure. In contrast, prior studies have reported little change in IPD rates in children aged  $\geq 5$  years with SCD after PCV7 licensure.<sup>18,50</sup> Reasons may include low IPD rate estimates before

PCV7 licensure,<sup>50</sup> or that initially after PCV7 licensure children with SCD who were older were not vaccinated, in contrast to data from this study. In this study, between 2010 and 2018, IPD incidence rates in both age groups, (eg, aged 0-4 years and 5-9 years), declined by 87% and 80%, respectively. Moreover, in both age groups, no IPD with PCV13 serotypes occurred after licensure of PCV13 although immunization with PCV13 was absent or incomplete among some children with SCD and IPD. These findings suggest that herd immunity in the general population contributed to the reduction of IPD incidence rate in SCD.<sup>17</sup>

Although this study is limited to 1 region in the United States, results may have implications for regions of Africa with high SCD prevalence.<sup>51</sup> In a meta-analysis of children with pneumococcal meningitis or septicemia hospitalized in Africa, the odds ratio for HbSS in the population with pneumococcal sepsis or meningitis was 26 times higher compared with respective cohorts of children without infection.<sup>52,53</sup> Although two-thirds of African children are reported to have received PCV13 vaccination,<sup>54</sup> herd immunity appears diminished,<sup>55</sup> and mortality in children with SCD remains high.<sup>56-58</sup> Children with SCD identified by screening,<sup>59-61</sup> including unvaccinated children who are older, should be offered pneumococcal vaccination. Hydroxyurea may also provide protection against IPD.<sup>62-65</sup> In a recent study of the incidence of all bloodstream infections in children with SCD between 2010 and 2019 at our institution, we comparably found significantly lower odds of infection in those who were prescribed hydroxyurea.<sup>47</sup>

Expanded-coverage vaccines PCV15 and PCV20 were approved for children in 2022<sup>16,66</sup> and 2023,<sup>67,68</sup> respectively. Assuming vaccine serotype crossprotection,<sup>35-37</sup> based on pooled data and the 25-year review presented here, PCV15, PCV20, and PCV21/V116 (in development) could offer protection against IPD with non-PCV13 serotypes, in 4% to 16%, 39% to 51%, and 80% to 92%, respectively, in children with SCD and IPD. In addition, PCV20 and PCV21/V116 could provide protection against 57% to 83% or 86% to 100% of pneumococcal isolates with serotypes causing meningitis or death, respectively. Administration of PPV23 (after PCV vaccination, not to blunt the immune response)<sup>69</sup> may offer some additional crossprotection against vaccine-related serotypes not provided by PCV15 or PCV20.<sup>35,37</sup> Other pneumococcal vaccines are in development.<sup>70</sup> Vaccine schedules could be amended or changed as more data become available.

A limitation of this study is that some children with SCD may not have been included if they received care in other, nonspecialized clinics or hospitals. Such children were previously found to be at a significantly increased risk of death from IPD.<sup>17</sup> Other limitations include that administration of penicillin prophylaxis immediately before IPD,<sup>13</sup> vaccination coverage of all children,<sup>17</sup> protective effect of hydroxyurea on IPD, and acute chest syndrome/pneumonia as an outcome, were not examined. Because of the limited geographical area of IPD surveillance, as well as small numbers in some IPD outcomes, data may not be entirely generalizable. Lastly, this study did not include analysis of IPD in patients with SCD after the first decade of life, who remain at risk.<sup>13,18,49</sup>

In conclusion, IPD remains a persistent, life-threatening risk in children with SCD, thus underscoring the need for vaccines with broader serotype coverage and continued IPD surveillance to identify emerging targets for vaccines and other prophylactic strategies.

## Acknowledgments

The authors thank Monica Farley for invaluable guidance, and the research administration staff at Morehouse School of Medicine and Children's Healthcare of Atlanta. The authors thank Victor Lui and Alice Lui, and staff and students at Perimeter Pediatrics for encouragement, administrative, and clerical support; the Centers for Disease Control and Prevention (CDC) Emerging Infections Program, Streptococcal laboratory for serotype and susceptibility results; and the Georgia Sickle Cell Data Collection program of the CDC for providing newborn screening data.

This work was supported by grants from the National Institutes of Health (1P20MD003383-01 and 1T90HG004004-01), and by grant support from the Abraham J. & Phyllis Katz Foundation, United States.

## Authorship

Contribution: T.V.A. was responsible for conception draft and review, methodology, resources, project supervision and administration, data curation, investigation, analysis, writing the original manuscript draft, and review and editing of the manuscript; M.A.M.Y. was responsible for conception review, methodology, project administration, data curation, investigation, analysis, writing the original manuscript draft, and review and editing of the manuscript; S.T. was responsible for conception review, methodology, project administration, data curation, investigation, analysis, writing the original manuscript draft, and review and editing of the manuscript; A.T. was responsible for conception review, methodology, project administration, data curation, investigation, analysis, writing the original manuscript draft, and review and editing of the manuscript; K.W.L. was responsible for conception review, methodology, project administration, data curation, investigation, analysis, writing the original manuscript draft, and review and editing of the manuscript; F.O. was responsible for investigation, supervision, resources, and project administration; P.A.L. was responsible for conception review, resources, investigation, writing the original manuscript draft, and review and editing of the manuscript; and I.Y. was responsible for conception review, investigation, writing the original manuscript draft, and review and editing of the manuscript.

Conflict-of-interest disclosure: I.Y. has received funding to her institution to conduct clinical research unrelated to this manuscript from the Gates Foundation, Centers for Disease Control and Prevention, National Institutes of Health, Moderna, and Pfizer; and consults for Merck and Sanofi-Pasteur. The remaining authors declare no competing financial interests.

ORCID profiles: K.W.L., 0000-0002-5761-7437; F.S.O., 0000-0003-3601-7309; I.Y., 0000-0002-8631-0020.

Correspondence: Thomas Adamkiewicz, Pediatric Hematology; Perimeter Pediatrics; 3020 Mercer University Drive, Atlanta, GA, 30341; email: [tadamkiewicz@msm.edu](mailto:tadamkiewicz@msm.edu).



## References

1. Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. *Lancet*. 2017;390(10091):311-323.
2. Lane PA, O'Connell JL, Lear JL, et al. Functional asplenia in hemoglobin SC disease. *Blood*. 1995;85(8):2238-2244.
3. Rogers ZR, Wang WC, Luo Z, et al. Biomarkers of splenic function in infants with sickle cell anemia: baseline data from the BABY HUG Trial. *Blood*. 2011;117(9):2614-2617.
4. Powars D, Overturf G, Weiss J, Lee S, Chan L. Pneumococcal septicemia in children with sickle cell anemia. Changing trend of survival. *JAMA*. 1981;245(18):1839-1842.
5. Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. *N Engl J Med*. 1986;314(25):1593-1599.
6. Robinson MG, Watson RJ. Pneumococcal meningitis in sickle-cell anemia. *N Engl J Med*. 1966;274(18):1006-1008.
7. Barrett-Connor E. Bacterial infection and sickle cell anemia. An analysis of 250 infections in 166 patients and a review of the literature. *Medicine (Baltimore)*. 1971;50(2):97-112.
8. Leikin SL, Gallagher D, Kinney TR, Sloane D, Klug P, Rida W. Mortality in children and adolescents with sickle cell disease. Cooperative Study of Sickle Cell Disease. *Pediatrics*. 1989;84(3):500-508.
9. Newborn Screening for Sickle Cell Disease and Other Hemoglobinopathies. *JAMA*. 1987;258(9):1205-1209.
10. Falletta JM, Woods GM, Verter JI, et al. Discontinuing penicillin prophylaxis in children with sickle cell anemia. *J Pediatr*. 1995;127(5):685-690.
11. National Heart, Lung, and Blood Institute. The Management of Sickle Cell Disease. National Institutes of Health; 2002. Accessed 10 February 2023. <https://www.nhlbi.nih.gov/sites/default/files/publications/04-2117.pdf>
12. Reeves SL, Freed GL, Madden B, et al. Trends in quality of care among children with sickle cell anemia. *Pediatr Blood Cancer*. 2022;69(2):e29446.
13. Adamkiewicz TV, Sarnaik S, Buchanan GR, et al. Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination. *J Pediatr*. 2003;143(4):438-444.
14. O'Brien KL, Swift AJ, Winkelstein JA, et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM(197) among infants with sickle cell disease. Pneumococcal Conjugate Vaccine Study Group. *Pediatrics*. 2000;106(5):965-972.
15. De Montalembert M, Abboud MR, Fiquet A, et al. 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): results of a phase 3 study. *Pediatr Blood Cancer*. 2015;62(8):1427-1436.
16. Quinn CT, Wiedmann RT, Jarovsky D, et al. Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) study. *Blood Adv*. 2023 Feb 14;7(3):414-421. <https://doi.org/10.1182/bloodadvances.2022008037>. PMID: 36383730; PMCID: PMC9979710.
17. Adamkiewicz TV, Silk BJ, Howgate J, et al. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life. *Pediatrics*. 2008;121(3):562-569.
18. Payne AB, Link-Gelles R, Azonobi I, et al. Invasive pneumococcal disease among children with and without sickle cell disease in the United States, 1998 to 2009. *Pediatr Infect Dis J*. 2013;32(12):1308-1312.
19. Moore MR, Link-Gelles R, Schaffner W, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study. *Lancet Respir Med*. 2016;4(5):399-406.
20. Moore MR, Link-Gelles R, Schaffner W, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. *Lancet Infect Dis*. 2015;15(3):301-309.
21. VAXNEUVANCE™. Prescribing information. FDA. 2021. Accessed 15 October 2021. <https://www.fda.gov/media/150819/download>
22. PREVNAR 20. Prescribing information. FDA. 2021. Accessed 15 October 2021. <https://www.fda.gov/media/149987/download>
23. Georgia Department of Public Health. Emerging Infections Program (EIP). 2020. Accessed 6 September 2020. <https://dph.georgia.gov/EIP>
24. United States Census Bureau. Census. 2021. Accessed 17 October 2021. <https://www.census.gov/quickfacts/fact/table/US/PST045219>. <http://censusviewer.com/state/GA>
25. Georgia Department of Public Health. Online Analytical Statistical Information System (OASIS), Web Query - Population Statistics, Office of Health Indicators for Planning (OHIP). Accessed 2 February 2019. <https://oasis.state.ga.us/>. <https://oasis.state.ga.us/oasis/webquery/help/DefPopulation.html>. 2019. Population Definitions
26. Georgia Department of Public Health. History of the Newborn Screening Program in Georgia. 2019. Accessed 27 January 2023. <https://dph.georgia.gov/document/publication/history-newborn-screening-program-georgia/download>
27. Harris MS, Eckman JR. Georgia's experience with newborn screening: 1981 to 1985. *Pediatrics*. 1989;83(5 pt 2):858-860.
28. Snyder AB, Lakshmanan S, Hulihan MM, et al. Surveillance for Sickle Cell Disease – Sickle Cell Data Collection Program, Two States, 2004–2018. *MMWR Surveill Summ*. 2022;71(No. SS-9):1-18.
29. National Heart, Lung, and Blood Institute. Evidence-Based Management of Sickle Cell Disease Expert Panel Report, 2014: Guide to Recommendations. National Institutes of Health. 2014. Accessed 9 June 2020. [https://www.nhlbi.nih.gov/sites/default/files/media/docs/Evd-Bsd\\_SickleCellDis\\_Rep2014.pdf](https://www.nhlbi.nih.gov/sites/default/files/media/docs/Evd-Bsd_SickleCellDis_Rep2014.pdf)

30. Centers for Disease Control and Prevention. Recommended childhood immunization schedule – United States, 2002. *MMWR Morb Mortal Wkly Rep.* 2002;51(2):31-33.
31. Centers for Disease Control and Prevention. Advisory Committee on immunization practices (ACIP) recommended immunization schedule for persons aged 0 through 18 years – United States, 2013. *MMWR Morb Mortal Wkly Rep.* 2013;62(1):2-8.
32. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). *Lancet.* 2011;377(9778):1663-1672.
33. Creary SE, Strouse JJ. Hydroxyurea and Transfusion Therapy for the Treatment of Sickle Cell Disease. *A Pocket Guide for the Clinician.* 2014. <https://www.hematology.org/-/media/hematology/files/education/clinicians/guidelines-quality/documents/sickle-cell-hydroxyurea.pdf>
34. Yildirim I, Kao CM, Tippett A, et al. A retrospective test-negative case-control study to evaluate influenza vaccine effectiveness in preventing hospitalizations in children. *Clin Infect Dis.* 2021;73(10):1759-1767.
35. Platt H, Omole T, Cardona J, et al. Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial. *Lancet Infect Dis.* 2023 Feb;23(2):233-246. PMID: 36116461.
36. Spencer BL, Shenoy AT, Orihuela CJ, Nahm MH. The pneumococcal serotype 15C capsule is partially O-acetylated and allows for limited evasion of 23-valent pneumococcal polysaccharide vaccine-elicited anti-serotype 15B antibodies. *Clin Vaccine Immunol.* 2017;24(8):e00099-17.
37. Hao L, Kuttel MM, Ravenscroft N, et al. Streptococcus pneumoniae serotype 15B polysaccharide conjugate elicits a cross-functional immune response against serotype 15C but not 15A. *Vaccine.* 2022;40(33):4872-4880.
38. Metcalf BJ, Gertz RE Jr, Gladstone RA, et al. Strain features and distributions in pneumococci from children with invasive disease before and after 13-valent conjugate vaccine implementation in the USA. *Clin Microbiol Infect.* 2016;22(1):60.e9-60.e29.
39. Centers for Disease Control and Prevention. Effects of new penicillin susceptibility breakpoints for Streptococcus pneumoniae– United States, 2006–2007. *MMWR Morb Mortal Wkly Rep.* 2008;57(50):1353-1355.
40. Johnson HL, Deloria-Knoll M, Levine OS, et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. *PLoS Med.* 2010 Oct 5;7(10):e1000348. PMID: 20957191; PMCID: PMC2950132.
41. Dayie NTKD, Tetteh-Ocloo G, Labi A-K, et al. Pneumococcal carriage among sickle cell disease patients in Accra, Ghana: risk factors, serotypes and antibiotic resistance. *PLoS One.* 2018;13(11):e0206728.
42. Usage Note 24188: Modeling Rates and Estimating Rates and Rate Ratios (With Confidence Intervals). SAS. 2015.
43. Broome CV, Facklam RR, Fraser DW. Pneumococcal disease after pneumococcal vaccination: an alternative method to estimate the efficacy of pneumococcal vaccine. *N Engl J Med.* 1980;303(10):549-552.
44. Fiore AE, Levine OS, Elliott JA, Facklam RR, Butler JC. Effectiveness of pneumococcal polysaccharide vaccine for preschool-age children with chronic disease. *Emerg Infect Dis.* 1999;5(6):828-831.
45. Rao SP, Rajkumar K, Schiffman G, Desai N, Unger C, Miller ST. Anti-pneumococcal antibody levels three to seven years after first booster immunization in children with sickle cell disease, and after a second booster. *J Pediatr.* 1995;127(4):590-592.
46. CDC. Sickle Cell Disease in Georgia. Accessed 22 June 2021. [https://www.cdc.gov/ncbddd/sicklecell/documents/SCD\\_in\\_GA\\_Prov.pdf](https://www.cdc.gov/ncbddd/sicklecell/documents/SCD_in_GA_Prov.pdf)
47. Yee ME, Lai KW, Bakshi N, et al. Bloodstream Infections in Children With Sickle Cell Disease: 2010-2019. *Pediatrics.* 2022 Jan 1;149(1):e2021051892. PMID: 34913059; PMCID: PMC8959248.
48. Greenhow TL, Hung Y-Y, Herz A. Bacteremia in Children 3 to 36 Months Old After Introduction of Conjugated Pneumococcal Vaccines. *Pediatrics.* 2017 Apr;139(4):e20162098. Epub 2017 Mar 10. PMID: 28283611.
49. Hord J, Byrd R, Stowe L, Windsor B, Smith-Whitley K. Streptococcus pneumoniae sepsis and meningitis during the penicillin prophylaxis era in children with sickle cell disease. *J Pediatr Hematol Oncol.* 2002;24(6):470-472.
50. Halasa NB, Shankar SM, Talbot TR, et al. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. *Clin Infect Dis.* 2007;44(11):1428-1433.
51. Piel FB, Adamkiewicz TV, Amendah D, Williams TN, Gupta S, Grosse SD. Observed and expected frequencies of structural hemoglobin variants in newborn screening surveys in Africa and the Middle East: deviations from Hardy-Weinberg equilibrium. *Genet Med.* 2016;18(3):265-274.
52. Ramakrishnan M, Moïsi JC, Klugman KP, et al. Increased risk of invasive bacterial infections in African people with sickle-cell disease: a systematic review and meta-analysis. *Lancet Infect Dis.* 2010;10(5):329-337.
53. Ramakrishnan M, Moïsi JC, Mpoudi-Etame M, Klugman KP, Feris J, Levine OS. Invasive infections and sickle-cell disease; Authors' reply. *Lancet Infect Dis.* 2010;10(9):593-594.
54. World Health Organization. *Pneumococcal Vaccination Coverage; 2023.* Accessed 12 February 2023. [https://immunizationdata.who.int/pages/coverage/PCV.html?CODE=Global+AFR&ANTIGEN=PCV3&YEAR=&ADVANCED\\_GROUPINGS=AFRO](https://immunizationdata.who.int/pages/coverage/PCV.html?CODE=Global+AFR&ANTIGEN=PCV3&YEAR=&ADVANCED_GROUPINGS=AFRO)
55. Bar-Zeev N, Swarthout TD, Everett DB, et al. Impact and effectiveness of 13-valent pneumococcal conjugate vaccine on population incidence of vaccine and non-vaccine serotype invasive pneumococcal disease in Blantyre, Malawi, 2006-18: prospective observational time-series and case-control studies. *Lancet Global Health.* 2021;9(7):e9-e99889.
56. Uyoga S, Macharia AW, Mochamah G, et al. The epidemiology of sickle cell disease in children recruited in infancy in Kilifi, Kenya: a prospective cohort study. *Lancet Global Health.* 2019;7(10):e1458-e1466.

57. Nnodu OE, Oron AP, Sopekan A, Akaba GO, Piel FB, Chao DL. Child mortality from sickle cell disease in Nigeria: a model-estimated, population-level analysis of data from the 2018 Demographic and Health Survey. *Lancet Haematol.* 2021;8(10):e723-e731.
58. Ranque B, Kitenge R, Ndiaye DD, et al. Estimating the risk of child mortality attributable to sickle cell anaemia in sub-Saharan Africa: a retrospective, multicentre, case-control study. *Lancet Haematol.* 2022;9(3):e208-e216.
59. Segbefia CI, Goka B, Welbeck J, et al. Implementing newborn screening for sickle cell disease in Korle Bu Teaching Hospital, Accra: results and lessons learned. *Pediatr Blood Cancer.* 2021;68(7):e29068.
60. Archer NM, Inusa B, Makani J, et al. Enablers and barriers to newborn screening for sickle cell disease in Africa: results from a qualitative study involving programmes in six countries. *BMJ Open.* 2022;12(3):e057623.
61. Nnodu OE, Sopekan A, Nnebe-Agumadu U, et al. Implementing newborn screening for sickle cell disease as part of immunisation programmes in Nigeria: a feasibility study. *Lancet Haematol.* 2020;7(7):e534-e540.
62. Lebensburger JD, Howard T, Hu Y, et al. Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectin. *Blood.* 2012;119(8):1915-1921.
63. Tshilolo L, Tomlinson G, Williams TN, et al. Hydroxyurea for children with sickle cell anemia in Sub-Saharan Africa. *N Engl J Med.* 2019;380(2):121-131.
64. Olupot-Olupot P, Tomlinson GA, Latham TS, et al. Effects of hydroxyurea treatment on malaria infections in Sub-Saharan Africa. *Blood.* 2019;134(suppl 1):522.
65. Abdullahi SU, Jibir BW, Bello-Manga H, et al. Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial. *Lancet Haematol.* 2022;9(1):e26-e37.
66. A study to evaluate the safety, tolerability, and immunogenicity of V114 in children with sickle cell disease (V114-023/PNEU-SICKLE). *ClinicalTrials.gov* identifier: NCT03731182. Updated 16 June. 2021. Accessed 10 October 2022. <https://ClinicalTrials.gov/show/NCT03731182>
67. PREVNAR 20. Prescribing information. *Pfizer.* 2021. Accessed 8 July 2023. <https://www.fda.gov/media/149987/download>
68. Kobayashi M. Evidence to Recommendations Framework and Policy Options: Use of 20-valent Pneumococcal Conjugate Vaccine in U.S. Children. 2023. Accessed 7 July 2023. <https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-06-21-23/04-Pneumococcal-Kobayashi-508.pdf>
69. Blum MD, Dagan R, Mendelman PM, et al. A comparison of multiple regimens of pneumococcal polysaccharide–meningococcal outer membrane protein complex conjugate vaccine and pneumococcal polysaccharide vaccine in toddlers. *Vaccine.* 2000;18(22):2359-2367.
70. Musher DM, Anderson R, Feldman C. The remarkable history of pneumococcal vaccination: an ongoing challenge. *Pneumonia (Nathan).* 2022;14(1):1-15.
71. John AB, Ramlal A, Jackson H, Maude GH, Sharma AW, Serjeant GR. Prevention of pneumococcal infection in children with homozygous sickle cell disease. *Br Med J (Clin Res Ed).* 1984;288(6430):1567-1570.
72. Williams TN, Uyoga S, Macharia A, et al. Bacteraemia in Kenyan children with sickle-cell anaemia: a retrospective cohort and case-control study. *Lancet.* 2009;374(9698):1364-1370.
73. McCavit TL, Quinn CT, Techasaensiri C, Rogers ZR. Increase in invasive *Streptococcus pneumoniae* infections in children with sickle cell disease since pneumococcal conjugate vaccine licensure. *J Pediatr.* 2011;158(3):505-507.
74. Baskin MN, Goh XL, Heeney MM, Harper MB. Bacteremia risk and outpatient management of febrile patients with sickle cell disease. *Pediatrics.* 2013;131(6):1035-1041.
75. Patel A, Zuzo A, Imran H, Siddiqui AH. Prevalence of pneumococcal bacteremia in children with sickle cell disease. *Pediatr Hematol Oncol.* 2013;30(5):432-436.
76. Navalkele P, Özgönenel B, McGrath E, Lephart P, Sarnaik S. Invasive pneumococcal disease in patients with sickle cell disease. *J Pediatr Hematol Oncol.* 2017;39(5):341-344.
77. Martin OO, Moquist KL, Hennessy JM, Nelson SC. Invasive pneumococcal disease in children with sickle cell disease in the pneumococcal conjugate vaccine era. *Pediatr Blood Cancer.* 2018;65(1):e26713.
78. Oligbu G, Collins S, Sheppard C, et al. Risk of invasive pneumococcal disease in children with sickle cell disease in England: a National Observational Cohort Study, 2010-2015. *Arch Dis Child.* 2018;103(7):643-647.